In vitro effect of D-004, a lipid extract of the fruit of the cuban royal palm (Roystonea regia), on prostate steroid 5α-reductase activity

Current Therapeutic Research - Clinical and Experimental

Volumn 67, Issue 6, 2006, Pages 396-405

  Pérez, L Yohani ^a   Menéndez, Roberto ^a   Má, Rosa ^a   González, Rosa M ^a  

^a NATL CENTER FOR SCIENTIFIC RESEARCH   (Cuba)

Author keywords

D 004; free fatty acids; prostate 5 reductase inhibitors; prostate hyperplasia

Indexed keywords

ACETONE; ANDROSTANOLONE; BENZENE; CARBOXYMETHYLCELLULOSE; CHLOROFORM; D 004; LIPID; PLANT EXTRACT; SILICA GEL; STEROID 5ALPHA REDUCTASE; STEROID 5ALPHA REDUCTASE INHIBITOR; STEROL; TESTOSTERONE; TRITIUM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARECACEAE; ARTICLE; CELL FREE SYSTEM; CONTROLLED STUDY; CUBA; DRUG INHIBITION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME KINETICS; ENZYME MECHANISM; ENZYME SUBSTRATE; EXPERIMENTAL STUDY; FRUIT; IN VITRO STUDY; INCUBATION TIME; INHIBITION KINETICS; MALE; MICHAELIS CONSTANT; NONHUMAN; PRIORITY JOURNAL; PROSTATE; RAT; ROYSTONEA REGIA; SUSPENSION CELL CULTURE; TISSUE HOMOGENATE; TISSUE PREPARATION;

EID: 34249942551     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.curtheres.2006.12.004     Document Type: Article

References (37)

1. Clifford G.M., and Farmer R.D. Medical therapy for benign prostatic hyperplasia: A review of the literature. Eur Urol 38 (2000) 2-19
2. Simpson R.J. Benign prostatic hyperplasia. Br J Gen Pract 47 (1997) 235-240
3. Barry M.J., and Roehrborn C.G. Benign prostatic hyperplasia [published correction appears in BMJ. 2002;324:775]. BMJ 323 (2001) 1042-1046
4. Thorpe A., and Neal D. Benign prostatic hyperplasia [published correction appears in Lancet. 2003;362:496]. Lancet 361 (2003) 1359-1367
5. Bhargava S., Canda A.E., and Chapple C.R. A rational approach to benign prostatic hyperplasia evaluation: Recent advances. Curr Opin Urol 14 (2004) 1-6
6. Bartsch G., Rittmaster R.S., and Klocker H. Dihydrotestosterone and the concept of 5alphareductase inhibition in human benign prostatic hyperplasia. Eur Urol 37 (2000) 367-380
7. Carson III C., and Rittmaster R. The role of dihydrotestosterone in benign prostatic hyperplasia. Urology 61 Suppl 1 (2003) 2-7
8. Bartsch G., Rittmaster R.S., and Klocker H. Dihydrotestosterone and the role of 5 alphareductase inhibitors in benign prostatic hyperplasia. Urologe A 41 (2002) 412-424
9. Michel M.C., Taguchi K., Schafers R.S., et al. α1-Adrenoceptor subtypes in the human cardiovascular and urogenital systems. Adv Pharmacol 42 (1998) 394-398
10. Sandhu J.S., and Te A.E. The role of 5-alpha-reductase inhibition as monotherapy in view of the MTOPS data. Curr Urol Rep 5 (2004) 274-279
11. Lam J.S., Romas N.A., and Lowe F.C. Long-term treatment with finasteride in men with symptomatic benign prostatic hyperplasia. 10-Year follow-up. Urology 61 (2003) 354-358
12. Oelke M., Hofner K., Berges R.R., and Jonas U. Drug therapy of benign prostatic hyperplasia syndrome with alpha 1-receptor blockers. Basic principles and clinical results. Urologe A 41 (2002) 425-441
13. Lowe F.C., Dreikorn K., Borkowski A., et al. Review of recent placebo-controlled trials utilizing phytotherapeutic agents for treatment of BPH. Prostate 37 (1998) 187-193
14. Plosker G.L., and Brogden R.N. Serenoa repens (permixon). A review of its pharmacology and therapeutic efficacy in benign prostate hyperplasia. Drugs Aging 9 (1996) 379-395
15. Wilt T., Ishani A., and Mac Donald R. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev 5 (2002) CD001423
16. Carraro J.C., Raynaud J.P., Koch G., et al. Comparison of phytotherapy (permixon) with finasteride in the treatment of benign prostate hyperplasia: A randomized international study of 1,098 patients. Prostate 29 (1996) 231-240
17. Aliaev I.G., Vinarov A.Z., Lokshin K.L., and Spivak L.G. Five-year experience in treating with prostatic hyperplasia patients with permixon (Serenoa repens Pierre Fabre Medicament). Urologia 1 (2002) 23-25
18. Debruyne F., Koch G., Boyle P., et al., Groupe d'etude PERMAL. Comparison of a phytotherapeutic agent (permixon) with an alpha-blocker (tamsulosin) in the treatment of benign prostatic hyperplasia: 1-Year randomized international study. Prog Urol 2 (2002) 384-392
19. Willetts K.E., Clements M.S., Champion S., et al. Serenoa repens extract for benign prostate hyperplasia: A randomized controlled trial. BJU Int 92 (2003) 267-270
20. Bent S., Kane C., Shinohara K., et al. Saw palmetto for benign prostatic hyperplasia. N Engl J Med 354 (2006) 557-566
21. Sultan C., Terraza A., Deviller C., et al. Inhibition of androgen metabolism and binding by a liposterolic extract of "Serenoa repens B" in human foreskin fibroblasts. J Steroid Biochern 20 (1984) 515-519
22. Weisser H., Tunn S., Behnke B., and Krieg M. Effects of the Sabal serrulata extract IDS 89 and its subfractions on 5alpha-reductase activity in human prostatic hyperplasia. Prostate 28 (1996) 300-306
23. Iehlé C.V., Délos S., Guirou O., et al. Human prostatic steroid 5 alpha-reductase isoforms-a comparative study of selective inhibitors. J Steroid Biochem Mol Biol 54 (1995) 273-279
24. Bayne C.W., Donnelly F., Ross M., and Habib F.K. Serenoa repens (permixon): A 5alpha-reductase types I and II inhibitor-new evidence in a coculture model of BPH. Prostate 40 (1999) 232-241
25. Habib F.K., Ross M., Ho C.K., et al. Serenoa repens (permixon) inhibits the 5alpha-reductase activity of human prostate cancer cell lines without interfering with PSA expression. Int J Cancer 114 (2005) 190-194
26. Raynaud J.P., Cousse H., and Martin P.M. Inhibition of type 1 and type 2 5alpha-reductase activity by free fatty acids, active ingredients of permixon. J Steroid Biochem Mol Biol 82 (2002) 233-239
27. Rhodes L., Primka R.L., Berman C., et al. Comparison of finasteride (proscar), a 5 alpha reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5 alpha reductase inhibition. Prostate 20 (1993) 43-51
28. Arruzazabala M.L., Carbajal D., Mas R., et al. Preventive effects of D-004, a lipid extract from Cuban royal palm (Roystonea regia) fruits, on testosterone-induced prostate hyperplasia in intact and castrated rodents. Drugs Exp Clin Res 30 (2004) 227-233
29. Carbajal D., Arruzazabala M.L., Mas R., et al. Effects of D-004, a lipid extract from Cuban royal palm fruit, on inhibiting prostatic hypertrophy induced with testosterone or dihydrotestosterone in a rat model: A randomized, controlled study. Curr Ther Res Clin Exp 65 (2004) 505-514
30. Noa M., Arruzazabala M.L., Carbajal D., et al. Effect of D-004, a lipid extract from Cuban royal palm fruit, on histological changes of prostate hyperplasia induced with testosterone in rats. Int J Tissue React 27 (2005) 203-211
31. Carbajal D., Molina V., Mas R., and Arruzazabala M.L. Therapeutic effect of D-004, a lipid extract from Roystonea regia fruits, on prostate hyperplasia induced in rats. Drugs Exp Clin Res 31 (2005) 193-197
32. George F.W., Russell D.W., and Wilson J.D. Feed-forward control of prostate growth: Dihydrotestosterone induces expression of its own biosynthetic enzyme, steroid 5 alpha-reductase. Proc Natl Acad Sci U S A 88 (1991) 8044-8047
33. Kitahara S., Higashi Y., Takeuchi S., and Oshima H. Relationship of changing steroid 5α-reductase activity to iododeoxyuridine uptake during regeneration of involuted prostates. Biol Rep 40 (1989) 793-799
34. Marxwell M.A., Haas S.M., Beiber L.L., and Tolbert N.E. A modification of the Lowry procedure to simplify protein determination in membrane lipoprotein samples. Anal Biochem 87 (1987) 206-209
35. Russell D.W., and Wilson J.D. Steroid 5-alpha reductase: Two genes/two enzymes. Annu Rev Biochem 63 (1994) 25-61
36. Bombardelli E., Morazzoni P., and Small J.K. Serenoa repens (bartram). Fitoterapia 68 (1997) 99-113
37. No. 2. Saw palmetto extract. Publication USP28-NF23. Expert Committee. United States pharmacopeial forum: (DSB) dietary supplement: Botanicals Vol. 28 (2005), Pharmacopeial Convention, Rockville, Md 425